CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV.

ABSTRACT: Hepatitis B remains a major global public health challenge, with particularly high prevalence in medically disadvantaged western Pacific and African regions. Although clinically available technologies for the qPCR detection of HBV are well established, research on point-of-care testing has not progressed substantially. The development of a rapid, accurate point-of-care test is essential for the prevention and control of hepatitis B in medically disadvantaged rural areas. The development of the CRISPR/Cas system in nucleic acid detection has allowed for pathogen point-of-care detection. Here, we developed a rapid and accurate point-of-care assay for HBV based on LAMP-Cas12a. It innovatively solves the problem of point-of-care testing in 10 min, particularly the problem of sample nucleic aci

SUBMITTER: Ding R 

PROVIDER: S-EPMC8125043 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature